At September 30, 2008, the company had liquid funds available for operating activities (cash and cash equivalents together with current investments) of $11.8 million, as compared to $23.7 million at ...
deCODE genetics, Inc. (DCGN) Q2 2008 Earnings Call Transcript August 7, 2008 8:00 AM ETExecutivesJoy Bessenger – VP of Strategy and Development, and Head of ...
REYKJAVIK, November 6 deCODE genetics (Nasdaq:DCGN) today announced its consolidated financial results for the quarterended September 30, 2008. A conference call to discuss the quarter's ...
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of diagnostics and drugs for common diseases. deCODE is a global leader in gene discovery - our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results